Tetanus Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Tetanus - Pipeline Review, H1 2015” to its store. The report provides an overview of the Tetanus’s therapeutic pipeline.

Tetanus Therapeutic Pipeline Market H2 2015

Tetanus Therapeutic Pipeline Market H2 2015

Past News Releases

RSS

The report “Tetanus - Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Tetanus. Tetanus is a acute infectious disease of humans and other animals, caused by toxins produced by the bacillus Clostridium tetani and characterized by rigidity and spasms of the voluntary muscles. The initial symptoms of tetanus include irritable and sore muscles. Muscles also get stiff and become cramped and body starts to feel tired. Swallowing food also becomes a problem. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/tetanus-pipeline-review-h1-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. Companies discussed in this Tetanus – Pipeline Review, H1 2015 report include Beijing Minhai Biotechnology Co., Ltd, Bharat Biotech International Limited, Biological E. Limited, Daiichi Sankyo Company, Limited, Green Cross Corporation, Indian Immunologicals Limited, LG Life Sciences, Ltd., Novartis AG, Panacea Biotec Limited, Prometheon Pharma, LLC, Sanofi, Sanofi Pasteur SA, Serum Institute of India Limited, Sinovac Biotech Ltd. and Zydus Cadila Healthcare Limited.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are (diphtheria + tetanus + pertussis (acelluar) + poliovirus (types 1, 2 ,3)) vaccine, (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza [serogroup B]) vaccine, diphtheria + pertussis + tetanus + hepatitis [serotype B] + haemophilus influenza [serotype B] vaccine, diphtheria + pertussis + tetanus vaccine, diphtheria + pertussis + tetanus vaccine, diphtheria + tetanus + pertussis (acellular) vaccine, diphtheria + tetanus + pertussis (acellular) vaccine, diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [type B] + polio (pentavalent) vaccine, diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [type B] + polio (hexavalent) vaccine, diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine, diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine, diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine, diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine, diphtheria + tetanus+ pertussis (whole cell) vaccine, diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine, diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine, diphtheria + tetanus + pertussis (whole-cell) vaccine, diphtheria + tetanus vaccine, DTaP Vaccine, GC-1107, GC-3111A, tetanus + diphtheria + pertussis (acellular) vaccine, tetanus vaccine and VN-0103. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=356481 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report include: Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program 78, Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine 78, Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age 79, Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 79, Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 80, Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 81, Jun 22, 2012: Sanofi Pasteur's Hexaxim Receives Positive Opinion From European Medicines Agency 82, Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis 83, Jun 13, 2005: U.S. FDA Licenses sanofi pasteur's ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis 83 and Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine 84.

Explore more reports on Pharmaceuticals industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@chinamrreport
Follow >
Market Reports China
Like >
Follow us on
Visit website